EGFR and neoplasm: The notion that epithelial phenotype directly correlates with the efficacy of EGFR targeted therapies was put forward when early clinical trials performed in non-selected NSCLC patients identified a link between tumor E-cadherin levels and response to first generation EGFR TKI erlotinib (Richardson et al., 2012).